AN2 Therapeutics

Historical price data

AN2 Therapeutics is focused on discovering and developing novel therapeutics derived from its boron chemistry platform, which enables the creation of selective inhibitors for challenging biological targets. The company has a pipeline of boron-based compounds in clinical and preclinical development for infectious diseases, including its lead candidate for Chagas disease. With experienced leadership from Anacor Pharmaceuticals and a commitment to global health, AN2 aims to deliver high-impact drugs to address critical unmet needs.

Boron-based drug discovery platform enabling creation of selective small molecule inhibitors through reversible covalent bonding, allowing targeting of biological pathways difficult to address with traditional carbon-based chemistry.

6 drugs in pipeline, 1 in Phase 3

Limited direct competition in Chagas disease and melioidosis, where current treatments are suboptimal. Differentiation through boron chemistry allows targeting of pathways inaccessible to traditional antibiotics. The platform builds on proven success from Anacor Pharmaceuticals, providing validation for the approach.